Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma

BACKGROUND: Despite the acknowledged predictive value of KRAS in immune checkpoint inhibitor (ICI) responses, the heterogeneous behavior of its mutations in this sphere remains largely unexplored. As of now, no studies have definitively categorized KRAS subtype variations as independent prognostic i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Tang, Zhuoran, Li, Chunyu, Li, Xuefei, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635421/
https://www.ncbi.nlm.nih.gov/pubmed/37954616
http://dx.doi.org/10.3389/fimmu.2023.1297588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635421/
https://www.ncbi.nlm.nih.gov/pubmed/37954616
http://dx.doi.org/10.3389/fimmu.2023.1297588

Ejemplares similares